NEW YORK (GenomeWeb News) – GVK Biosciences today said that it has extended its license for its Clinical Biomarker Database to the US Food and Drug Administration.
The extension is for a license, originally forged in 2007, to the database with FDA's Biomarker Qualification Group.
Financial and other terms of the extension were not disclosed.
The database called GoBiom is a collection of all clinically evaluated exploratory and preclinical biomarkers that are associated with different therapeutic areas reported in global clinical trials, and clinical and preclinical studies, GVK said. It contains data on 12,000 biochemical, genomic, imaging, metabolite, cellular, and physiological biomarkers with multiple data points covering experimental, analytical, clinical, and statistical data.